Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DFTX Definium Therapeutics

已收盘 08-05 16:00:00 EDT

44.39

+2.07

+4.89%

盘后44.35

-0.04-0.09%

19:53 EDT

最高44.53	最低42.06	成交量156.24万
今开42.50	昨收42.32	日振幅5.82%
总市值57.71亿	流通市值55.55亿	总股本1.30亿
成交额6,841万	换手率1.25%	流通股本1.25亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":44.39,"timestamp":1785960000000,"preClose":42.32,"halted":0,"volume":1562405,"hourTrading":{"tag":"盘后","latestPrice":44.35,"preClose":44.39,"latestTime":"19:53 EDT","volume":15084,"amount":668986.6053,"timestamp":1785974031304,"change":-0.04,"changeRate":-0.000901,"amplitude":0.008786},"delay":0,"changeRate":0.04891304347826088,"floatShares":125130818,"shares":130000000,"eps":-2.49367,"marketStatus":"已收盘","change":2.07,"latestTime":"08-05 16:00:00 EDT","open":42.5,"high":44.525,"low":42.06,"amount":68407440.57472,"amplitude":0.058247,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.49367,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786003200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":42.32,"preHourTrading":{"tag":"盘前","latestPrice":42.48,"preClose":42.32,"latestTime":"09:29 EDT","volume":2068,"amount":87656.278776,"timestamp":1785936599999,"change":0.16,"changeRate":0.003781,"amplitude":0.024069},"postHourTrading":{"tag":"盘后","latestPrice":44.35,"preClose":44.39,"latestTime":"19:53 EDT","volume":15084,"amount":668986.6053,"timestamp":1785974031304,"change":-0.04,"changeRate":-0.000901,"amplitude":0.008786},"volumeRatio":0.83915,"optionData":{"bulkOrders":[{"symbol":"DFTX","call":true,"expireDate":1787284800000,"strike":"60.0","timestamp":1785941960134,"price":0.4,"volume":3616,"amount":144640,"type":"-"},{"symbol":"DFTX","call":true,"expireDate":1787284800000,"strike":"45.0","timestamp":1785941960133,"price":4.1,"volume":3616,"amount":1482560,"type":"+"}]},"impliedVol":1.2522,"impliedVolPercentile":0.8551},"requestUrl":"/m/hq/s/DFTX","defaultTab":"news","newsList":[{"id":"1113882972","title":"Definium Therapeutics 启动“焦虑之源”计划，携手医疗提供者深化广泛性焦虑症患者影响及神经生物学认知","url":"https://stock-news.laohu8.com/highlight/detail?id=1113882972","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113882972?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:01","pubTimestamp":1784199702,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 宣布启动一项名为“焦虑之源”的医疗提供者倡议。该计划旨在推动医学界对广泛性焦虑症（GAD）患者所面临的影响及其背后神经生物学机制的理解，以期促进更有效的临床诊疗策略发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182980299","title":"异动解读｜Definium Therapeutics盘前上涨5.1%，DT120三期数据利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1182980299","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182980299?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:46","pubTimestamp":1784191619,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics盘前上涨5.1%，报48.0美元/股，成交额6.29万美元。随后公司成功完成8.05亿美元增发募资，承销商全额行使超额配售权，募资用于DT120商业化准备及研发推进。RBC Capital将目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级，当前股价仍低于该目标价，市场买盘动能延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Definium Therapeutics盘前上涨5.1%，DT120三期数据利好持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154657006","title":"异动解读｜Definium Therapeutics夜盘上涨7.03%，DT120三期数据利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1154657006","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154657006?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:47","pubTimestamp":1784162870,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics夜盘上涨7.03%，报48.87美元/股，成交额1.91万美元。消息面上，公司此前公布其核心候选药物DT120口崩片治疗重度抑郁症的3期EMERGE研究取得积极顶线结果，主要终点及所有关键次要疗效终点均达成，显示出统计学显著性和临床意义的优势。随后公司成功完成8.05亿美元增发募资，承销商全额行使超额配售权。RBC Capital将目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级，当前股价仍低于该目标价，市场买盘动能延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127959646","title":"异动解读｜Definium Therapeutics盘后上涨5.04%，报47.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127959646","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127959646?lang=zh_cn&edition=full","pubTime":"2026-07-16 06:57","pubTimestamp":1784156250,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics盘后上涨5.04%，报47.79美元/股，成交额141.84万美元。Definium Therapeutics所在的制药行业中，个股中，礼来涨0.03%，强生涨0.36%，默沙东涨0.02%，辉瑞跌0.12%，施贵宝跌0.0%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111295043","title":"异动解读｜Definium Therapeutics盘中下跌5.44%，报44.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111295043","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111295043?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:21","pubTimestamp":1783952499,"startTime":"0","endTime":"0","summary":"7月13日，Definium Therapeutics盘中下跌5.44%，报44.47美元/股，成交额1282.29万美元。Definium Therapeutics所在的制药行业中，个股中，礼来跌0.21%，辉瑞涨1.78%，强生涨0.03%，Crinetics Pharmaceuticals涨0.06%，阿斯利康跌1.47%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142071966","title":"异动解读｜Definium Therapeutics盘中下跌5.06%，报46.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142071966","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142071966?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:51","pubTimestamp":1783691501,"startTime":"0","endTime":"0","summary":"7月10日，Definium Therapeutics盘中下跌5.06%，报46.0美元/股，成交额912.92万美元。Definium Therapeutics所在的制药行业中，个股中，礼来跌2.01%，强生涨0.17%，阿斯利康跌2.55%，Crinetics Pharmaceuticals涨0.05%，默沙东跌0.42%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143979950","title":"异动解读｜Definium Therapeutics盘中上涨5.09%，DT120三期临床成功叠加巨额融资提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1143979950","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143979950?lang=zh_cn&edition=full","pubTime":"2026-07-09 23:53","pubTimestamp":1783612422,"startTime":"0","endTime":"0","summary":"7月9日，Definium Therapeutics盘中上涨5.09%，报47.625美元/股，成交额6690.95万美元。消息面上，公司此前公布其核心产品DT120口崩片治疗重度抑郁症的3期EMERGE研究取得积极顶线结果，达到主要终点及所有关键次要疗效终点，安全性特征良好。RBC Capital随之将目标价由36美元大幅上调至57美元，维持\"跑赢大市\"评级。关键临床数据验证叠加充裕资金保障，持续推动股价上行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137042231","title":"异动解读｜Definium Therapeutics盘中下跌5.02%，报44.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137042231","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137042231?lang=zh_cn&edition=full","pubTime":"2026-07-01 23:49","pubTimestamp":1782920992,"startTime":"0","endTime":"0","summary":"7月1日，Definium Therapeutics盘中下跌5.02%，报44.68美元/股，成交额4259.27万美元。Definium Therapeutics所在的制药行业中，个股中，礼来跌0.61%，强生跌0.66%，辉瑞跌0.69%，默沙东跌1.49%，诺和诺德涨2.69%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142122370","title":"异动解读｜Definium Therapeutics盘中上涨5.04%，DT120三期临床积极叠加8亿美元增发落地提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1142122370","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142122370?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:03","pubTimestamp":1782828238,"startTime":"0","endTime":"0","summary":"6月30日，Definium Therapeutics盘中上涨5.04%，报48.84美元/股，成交额2163.95万美元。消息面上，公司近期利好密集释放。随后公司迅速启动增发融资，最终以每股34美元完成约2370万股的扩大规模公开发行，募资总额达8.05亿美元，承销商全额行使超额配售权，反映市场认购需求旺盛。此外，RBC Capital将公司目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160379075","title":"Definium Therapeutics 宣布完成8.05亿美元增发，承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1160379075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160379075?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:25","pubTimestamp":1782419116,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 公司已成功完成其增发规模达8.05亿美元的公开募股。此次发行规模较原计划有所扩大，并包含了承销商全额行使购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111531466","title":"异动解读｜Definium Therapeutics盘中上涨9.07%，核心管线3期研究达成主要终点及7亿美元增发定价落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1111531466","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111531466?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:26","pubTimestamp":1782397562,"startTime":"0","endTime":"0","summary":"6月25日，Definium Therapeutics盘中上涨9.07%，报45.595美元/股，成交额9796.98万美元。消息面上，公司于6月22日宣布其候选药物DT120口崩片在治疗重度抑郁症的关键3期EMERGE研究中达成主要终点及所有关键次要疗效终点，显示出统计学显著性和临床意义的改善。随后RBC Capital将目标价从36美元大幅上调至57美元，维持跑赢大盘评级。此外，公司于6月24日完成7亿美元扩大规模包销公开发行定价，每股34美元，募资将用于研发及一般企业用途。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186956929","title":"异动解读｜Definium Therapeutics盘中上涨15.48%，核心管线3期研究达成主要终点叠加投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186956929","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186956929?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:00","pubTimestamp":1782309630,"startTime":"0","endTime":"0","summary":"6月24日，Definium Therapeutics盘中上涨15.48%，报42.42美元/股，成交额1.56亿美元。消息面上，公司于6月22日宣布其候选药物DT120口崩片在治疗重度抑郁症的关键3期EMERGE研究中取得积极顶线结果，达成主要终点及所有关键次要疗效终点，显示出与安慰剂相比具有统计学显著性和临床意义的改善，安全性特征与先前研究一致。随后RBC Capital将公司目标价从36美元大幅上调至57美元，维持跑赢大盘评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645889615","title":"Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645889615","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645889615?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:11","pubTimestamp":1782292315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 临床后期生物制药公司Definium Therapeutics 正式宣布，其已完成扩大规模的包销公开发行定价，公司将以每股34.00美元的价格公开发行20,588,236股普通股。在不扣除承销折扣、佣金及其他发行费用的情况下，Definium预计此次公开发行的募资总额将达到约7亿美元。本次发行预计将于2026年6月25日左右交割。而就在本次发行定价前不久，Definium刚于6月22日宣布，其用于治疗重度抑郁症的创新疗法“DT120口崩片”在3期临床研究中取得了积极的顶线结果。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UUP","BK4007","DFTX","LENZ","BK4539","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109486940","title":"Definium Therapeutics公布DT120口崩片治疗重度抑郁症的3期EMERGE研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1109486940","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109486940?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:00","pubTimestamp":1782126018,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其针对重度抑郁症（MDD）的候选药物DT120口崩片（ODT）在关键的3期EMERGE研究中取得了积极的顶线结果。该研究达到了其主要终点，显示出与安慰剂相比，在改善抑郁症状方面具有统计学显著性和临床意义的优势。安全性特征与先前研究一致，未发现新的安全问题。这一积极数据为DT120的后续监管申请奠定了坚实基础，标志着公司在精神疾病治疗领域的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147229029","title":"Definium Therapeutics：DT120口崩片研究达成主要及所有关键次要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1147229029","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147229029?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:00","pubTimestamp":1782126016,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其候选药物DT120口崩片的一项临床研究，已成功达成预设的主要疗效终点以及所有关键性的次要疗效终点。这一积极结果标志着该药物在目标适应症的开发中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194348262","title":"Definium Therapeutics将于2026年6月22日讨论重度抑郁症III期EMERGE研究的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1194348262","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194348262?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:01","pubTimestamp":1782075697,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，将于2026年6月22日就其针对重度抑郁症的III期EMERGE研究的顶线结果进行讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137501338","title":"Definium Therapeutics宣布在DT120 Odt针对重度抑郁症的第二个三期关键研究“Ascend”中完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1137501338","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137501338?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583709,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，在其针对重度抑郁症的候选药物DT120 Odt的第二个关键性三期临床试验“Ascend”中，已完成对首例患者的给药。这标志着该药物临床开发项目的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180337716","title":"Definium Therapeutics 研发DT120口腔崩解片 针对广泛性焦虑症、重度抑郁症及其他严重脑健康疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1180337716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180337716?lang=zh_cn&edition=full","pubTime":"2026-04-19 07:43","pubTimestamp":1776555796,"startTime":"0","endTime":"0","summary":"Definium Therapeutics公司正在积极推进其核心产品DT120口腔崩解片的研发进程，该药物主要瞄准广泛性焦虑症、重度抑郁症以及其他一系列严重的脑健康疾病的治疗领域。\n这款名为DT120 ODT的创新疗法，展现了公司在精神健康与神经系统疾病治疗方面的前沿探索。其研发策略聚焦于解决当前临床未满足的重大需求，旨在为深受相关疾病困扰的患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100586830","title":"Piper Sandler 首予 Definium Therapeutics 增持评级，目标价49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100586830","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100586830?lang=zh_cn&edition=full","pubTime":"2026-04-10 11:31","pubTimestamp":1775791902,"startTime":"0","endTime":"0","summary":"投资银行 Piper Sandler 宣布，正式开始对生物制药公司 Definium Therapeutics Inc 进行覆盖研究，并给予其“增持”评级。该机构设定了49美元的目标股价，显示出对其未来增长潜力的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101183436","title":"Definium Therapeutics现金储备雄厚：截至2025年底持有4.116亿美元现金及投资，预计可支撑运营至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1101183436","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101183436?lang=zh_cn&edition=full","pubTime":"2026-02-27 05:45","pubTimestamp":1772142302,"startTime":"0","endTime":"0","summary":"生物制药公司Definium Therapeutics（股票代码：DFTX）宣布，截至2025年12月31日，公司持有的现金、现金等价物及投资总额达到4.116亿美元。这一强劲的财务状况预计将为公司的持续运营提供充足资金，支撑其业务发展直至2028年。\n巨额的资金储备为Definium Therapeutics推进其研发管线提供了坚实保障。公司专注于创新疗法的开发，充足的资金使其能够在不依赖额外融资的情况下，持续投入关键研发项目并拓展临床研究。这一财务优势不仅增强了公司的运营稳定性，也为其长期战略目标的实现奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":-0.0423},{"period":"3month","weight":0.807},{"period":"6month","weight":1.6043},{"period":"1year","weight":3.5214},{"period":"ytd","weight":2.1606}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Definium Therapeutics, Inc.于2010年根据不列颠哥伦比亚省法律成立。他们是一家处于后期阶段的临床生物制药公司，正在开发新的候选产品来治疗大脑健康障碍。他们的使命是通过将科学的严谨性应用于迷幻药，锻造精神病学的新时代，目标是开发可获得的治疗方法，以大规模解锁愈合。他们正在开发一系列针对神经递质通路的创新候选产品，这些通路在大脑健康疾病中发挥着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.072082},{"month":4,"riseRate":0.8,"avgChangeRate":0.037703},{"month":5,"riseRate":0.5,"avgChangeRate":0.01554},{"month":6,"riseRate":0.5,"avgChangeRate":0.064762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.160554},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.080885},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Definium Therapeutics(DFTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Definium Therapeutics(DFTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}